Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS

• Published in: Nature neuroscience Vol. 8; no. 1; pp. 85 - 92
• Main Authors: Carmeliet, Peter, Storkebaum, Erik, Lambrechts, Diether, Dewerchin, Mieke, Moreno-Murciano, Maria-Paz, Appelmans, Saskia, Oh, Hideyasu, Van Damme, Philip, Rutten, Bart, Man, Wing Yan, De Mol, Maria, Wyns, Sabine, Manka, David, Vermeulen, Kristel, Van Den Bosch, Ludo, Mertens, Nico, Schmitz, Christoph, Robberecht, Wim, Conway, Edward M, Collen, Désiré, Moons, Lieve
• Format: Journal Article
• Language: English
• Published: United States Nature Publishing Group 01.01.2005
• Subjects: Amyotrophic lateral sclerosis; Amyotrophic Lateral Sclerosis - genetics; Amyotrophic Lateral Sclerosis - physiopathology; Animals; Axonal Transport; Cell Survival - drug effects; Diagnosis; Disease Models, Animal; Humans; Injections, Intraventricular; Motor neurons; Motor Neurons - drug effects; Nerve Degeneration - physiopathology; Neuromuscular Junction - drug effects; Neuroprotective Agents - administration & dosage; Neuroprotective Agents - pharmacokinetics; Neuroprotective Agents - pharmacology; Physiological aspects; Rats; Rats, Sprague-Dawley; Rats, Wistar; Recombinant Proteins - administration & dosage; Recombinant Proteins - pharmacology; Risk factors; Superoxide Dismutase - genetics; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - administration & dosage; Vascular Endothelial Growth Factor A - pharmacokinetics; Vascular Endothelial Growth Factor A - pharmacology; Belgium

Neurotrophin treatment has so far failed to prolong the survival of individuals affected with amyotrophic lateral sclerosis (ALS), an incurable motoneuron degenerative disorder. Here we show that intracerebroventricular (i.c.v.) delivery of recombinant vascular endothelial growth factor (Vegf) in a...